MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 0.5% Higher – What’s Next?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s stock price rose 0.5% on Monday . The company traded as high as $1.93 and last traded at $1.89. Approximately 93,117 shares were traded during trading, a decline of 69% from the average daily volume of 299,867 shares. The stock had previously closed at $1.88.

MAIA Biotechnology Stock Up 0.5 %

The company has a market capitalization of $49.44 million, a price-to-earnings ratio of -1.37 and a beta of 0.20.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.21. Equities research analysts predict that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.

Insider Buying and Selling

In other news, Director Stan Smith purchased 25,000 shares of MAIA Biotechnology stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $1.87 per share, with a total value of $46,750.00. Following the completion of the transaction, the director now directly owns 1,130,060 shares of the company’s stock, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 36.98% of the stock is owned by insiders.

Institutional Investors Weigh In On MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. XTX Topco Ltd purchased a new stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 10,991 shares of the company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.